Cargando…
A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis
COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To eval...
Autores principales: | Pappa, Vasiliki, Bouchla, Anthi, Terpos, Evangelos, Thomopoulos, Thomas P., Rosati, Margherita, Stellas, Dimitris, Antoniadou, Anastasia, Mentis, Andreas, Papageorgiou, Sotirios G., Politou, Marianna, Kotanidou, Anastasia, Kalomenidis, Ioannis, Poulakou, Garyfalia, Jahaj, Edison, Korompoki, Eleni, Grigoropoulou, Sotiria, Hu, Xintao, Bear, Jenifer, Karaliota, Sevasti, Burns, Robert, Pagoni, Maria, Trontzas, Ioannis, Grouzi, Elisavet, Labropoulou, Stavroula, Stamoulis, Kostantinos, Bamias, Aristotelis, Tsiodras, Sotirios, Felber, Barbara K., Pavlakis, George N., Dimopoulos, Meletios- Athanasios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069820/ https://www.ncbi.nlm.nih.gov/pubmed/33920489 http://dx.doi.org/10.3390/microorganisms9040806 |
Ejemplares similares
-
P1629: ADMINISTRATION OF CONVALESCENT PLASMA FOR THE TREATMENT OF SEVERE COVID-19: RESULTS OF A MULTICENTER PHASE II TRIAL
por: Thomopoulos, T., et al.
Publicado: (2022) -
Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma
por: Thomopoulos, Thomas P., et al.
Publicado: (2021) -
Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
por: Terpos, Evangelos, et al.
Publicado: (2020) -
Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study
por: Terpos, Evangelos, et al.
Publicado: (2020) -
SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors
por: Terpos, Evangelos, et al.
Publicado: (2021)